ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Altimmune Inc. continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat to slightly higher versus Monday’s close. Intraday ranges have been tight so far, with trading largely clustered between about $4.8 and $5.2 per share. INDmoney

NASDAQ:ALT · Pharmaceutical Industry · Stock Market

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly heads into the weekend of November 22, 2025, sitting near record highs and fresh off becoming the first drugmaker ever to join the $1 trillion market‑cap club. A powerful combination of blockbuster obesity drugs, new access deals with the U.S. government and employers, and bullish analyst sentiment is keeping LLY at the center of Wall Street’s attention. Reuters+1
22 November 2025
··
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer headlines today include a $41.5 million ADHD drug settlement with Texas, a new antibody discovery deal with Nona Biosciences, and fresh guidance on cost cuts and obesity drugs from the Jefferies Healthcare Conference — here’s what it all means for PFE stock on November 19, 2025.
19 November 2025
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions include a 40‑year tranche initially talked around ~125 bps over Treasuries, according to Bloomberg reporting on the transaction. A separate Reuters alert flagged a seven‑part notes offering in a fresh SEC filing, with sizing to be finalized at pricing. Together, the moves point to active balance‑sheet management following the Metsera close. Bloomberg Law+1
18 November 2025
·····
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN shares rocketing higher and triggered immediate legal and regulatory attention, making this one of the most closely watched biotech deals of the day. GlobeNewswire
13 November 2025
···
Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin therapies for myeloproliferative neoplasms and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. GlobeNewswire
10 November 2025
··
Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings reportstockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now only a few points shy of its 52-week peak of $43.72investing.com.
5 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings.
4 November 2025
·····
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” and “vue”, reflecting a vision of insight-driven careen.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter medicines to skincare and baby care. Today its portfolio spans three segmentsinvesting.com:
4 November 2025
···
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor by over 50%proclinical.comproclinical.com. Zoetis continues to leverage this scale and innovation engine in 2025, focusing on pet care growth while managing challenges in livestock.
4 November 2025
··
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89 the day priorstockinvest.us. That single-day gain of +30.8% crowned CURR as one of the market’s top percentage gainers. In fact, the stock has rallied five days in a row, more than doubling amid surging volumestockinvest.us. This momentum continued into Nov 3, with an opening trade around $3.52 and only a modest pullback from last week’s peak. By comparison, the share price was mere pennies over the summer, reflecting a 1-for-### reverse split that helped propel the nominal price into dollars. Investors who held through the restructuring have seen a dramatic rebound in value in recent weeks.
3 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39ts2.techstockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21stockanalysis.com, versus an average of only ~14 million in prior monthstipranks.com. In recent days, RANI dipped as low as ~$1.42 but rebounded sharply on Oct 31. Year-to-date the stock is still well off its 2021 highs, but the October news has put it in breakout mode.
31 October 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 Marketbeat. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector Nasdaq. By comparison, an index of large pharmaceutical stocks was up modestly, making BMY one of 2025’s laggards.
30 October 2025
··
Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna (CI) Rallies on Q3 Beat & Rebate-Free Drug Plan – Is a 25% Upside in Sight?

Cigna’s stock has pulled back modestly in late October after a strong run earlier in the year. According to market data, CI closed at $299.12 on Oct 29, 2025, down about 3% from the previous closestockanalysis.com. The dip followed weakness in broader managed-care stocks amid concerns about healthcare costs and policy. In pre-market trading Oct 30, CI rebounded to about $303reuters.com. Over the past year, CI shares have traded between roughly $257 and $350stockanalysis.com, reflecting volatility in the insurance sector.
30 October 2025
···
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – which tests NTLA-2001 in transthyretin amyloidosis patients with cardiomyopathy – experienced Grade 4 elevations in liver enzymes and bilirubin after receiving the one-time gene therapy reuters.com ca.investing.com. This met the trial’s pre-specified safety threshold for a mandatory pause.
27 October 2025
···
1 … 7 8 9 10
Follow on Google News
Add as preferred source Open in Google News